


FIGURE 1A



409470 66952660

FIGURE 1B




FIGURE 1C




FIGURE 2A




[illegible]

FIGURE 3





FIGURE 4



□ 1.56 µg; ○ 0.78 µg V1J:gD DNA; ◆ saline

△ 200, 100, 25, 12.5,
6.25, 3.13 µg

FIGURE 5




FIGURE 6

Effect of V1Jns:gB Immunization on HSV Infection [gB I]




FIGURE 7

WLM 93.9 Challenge of gC and ICP27 (DNA) Immunized Mice




FIGURE 8

<u>Group^a</u>	<u>Survivors/ Total (%)</u>	<u>Mean Day to Death</u>	<u>Paralyzed/ Total (%)</u>	<u>Vaginal Virus Titer^b</u>		
				<u>Day 2^c</u>	<u>Day 4</u>	<u>Day 6</u>
Vaccine, 10 µg	8/10 (80)	12.5 ± 0.7	5/10 (50)	3.8 ± 1.9	2.3 ± 1.2	<1.5 ± 0.0
Vaccine, 100 µg	10/10 (100) [†]	>21	0/10 (0)*	3.0 ± 1.3 ^ø	2.0 ± 0.7 [†]	<1.5 ± 0.0
Placebo	6/10 (60)	14.8 ± 4.0	8/10 (80)	5.0 ± 2.3	3.1 ± 1.4	1.6 ± 0.3

a The vaccine was administered intramuscularly 11 and 4 weeks prior to virus challenge.

b Log10 cell culture infections doses per ml, determined from vaginal swabs.

c After virus inoculation.

* P<0.001.

† P=0.008, ø P=0.06.

FIGURE 9

Effect of V1J:gD Immunization on HSV Vaginal Lesions in Guinea Pigs




FIGURE 10





FIGURE 11




FIGURE 12




FIGURE 13





FIGURE 14





FIGURE 15

